That rare moment in which @HollyLynchez & I disagree, at least at the margins, about the permissibility of pay-to-play clinical trials. From @RebeccaDRobbins @statnews. https://www.statnews.com/2019/08/06/amid-rising-concern-pay-to-play-clinical-trials-are-drawing-federal-scrutiny/ …
-
-
If the risk-benefit balance isn't acceptable, do not pass go. If there isn't a compelling rationale for charging subjects rather than using traditional mechanisms, do not pass go.
-
But I also want to be clearer than the story: I don't speak for SACHRP. I'm no longer on the committee. I sit on the subcommittee and have helped work on a draft for SACHRP's consideration. They could ultimately decide to go a completely different direction.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.